Loading...

Medlab Clinical Limited

MDC.AX•ASX
HealthcareBiotechnology
$6.60
$0.00(0.00%)

Medlab Clinical Limited (MDC.AX) Stock Overview

Explore Medlab Clinical Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-98.67%
↓ 98.67%
Profit Growth
$-0.93
↑ 68.57%
EPS Growth
$-0.93
↑ 68.69%
Operating Margin
-18989.10%
↑ 68.76%
ROE
274.67%
↑ 68.57%
Dividend Yield
0.00%
Analyst Recommendations data is not available for MDC.AXAnalyst Recommendations details for MDC.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

CEO

Dr. Sean Michael Hall

Employees

14

Headquarters

Building A, Botany, NSW

Founded

2015

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.